A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Purpose: Metastatic pancreatic adenocarcinoma (mPC) has a poor prognosis. CDK4/6 is often deregulated in mPC due to CDKN2A loss, resulting in the loss of p16INK4a that inhibits CDK4/6. CDK4/6 inhibitor monotherapy is ineffective due to RAS-mediated activation of alternative pathways, including phosp...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Pancreat Cancer
Auteurs principaux: Weinberg, Benjamin A., Wang, Hongkun, Witkiewicz, Agnieszka K., Marshall, John L., He, Aiwu R., Vail, Paris, Knudsen, Erik S., Pishvaian, Michael J.
Format: Artigo
Langue:Inglês
Publié: Mary Ann Liebert, Inc., publishers 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337242/
https://ncbi.nlm.nih.gov/pubmed/32642630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pancan.2020.0005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires